The University of California (UC) has encountered a significant legal setback in South Africa after the Johannesburg High Court revoked its patent for Xtandi. This prostate cancer drug extends life. This ruling paves the way for generic versions of the medication to be sold in the country, potentially lowering patient costs. Xtandi, developed at UC with funding from the National…